. In a previous study, we developed a method to quantify both cross-links, pyridinoline and pentosidine, in hydrolysates of human urine [10] and serum [5] Because the concentrations of pentosidine in urine were expressed as gmol/mol creatinine, we determined the creatinine content of aliquots of the urine samples enzymatically, using a Shimadzu CL-20 clinical chemistry analyzer (Shimadzu, Kyoto, Japan).
HPLC INSTRUMENTATION AND PROCEDURE
The HPLC system consisted of a Model CCPM-H pump, which has two pumps, a Model FS-8010 spectrofluorometer, a
Model UV-8010C ultraviolet absorbance detector, a Model VC-8020 six-port switching valve, a Model SD-8022 air vacuum pump, a Model AS-8020 autosampler, and a Model SC-8020 super system controller (all from Tosoh, Tokyo, Japan). A gel-filtration column, TSK precolumn PW (4.6 mm X 3.5 cm), was used as column 1, and an octadecylsilyl column, TSK-GEL ODS-80T (4.6 mm x 15 cm), was used as column 2 (both columns from Tosoh). The mobile phase for column 1 was 50 mL/L acetonitrile containing 30 mmol/L HFBA; the mobile phase for column 2 was 200 mL/L acetonitrile containing 30 mmol/L HFBA. The flow rate was 1.0 mL/min. Detector 1, which detected absorbance at 297 nm, monitored the separation of analyte on column 1. Detector 2, a spectrofluorometer, detected pentosidine eluted from column 2 (emission 385 nm, excitation 335 nm).
A schematic diagram of the HPLC system with the columnswitching valve is shown in Fig. 1 . At time zero, we injected sample onto column 1 and eluted with mobile phase 1, while column 2 was eluted with mobile phase 2 (valve position A). Just before the pentosidine was eluted from column 1, the valve was switched to position B and the eluate fraction containing pentosidine was introduced into column 2. After the transfer of pentosidine to column 2, the valve was switched back to position A. Then, the pentosidine-containing eluate from column I was further separated by column 2 and detected by detector 2; during this time, column 1 was washed and conditioned with mobile phase 1 until the next injection of sample. Thus, at 2.8 mm after sample injection, the valve was switched to position B; at 4.2 mm, it was switched back to position A. All operations were performed automatically and sequentially by the autosampIer and the system controller. Sample injection volumes were 5-160 gL, depending on the experimental conditions. For routine analysis of samples without hydrolysis, 60 gL of urine or 5 gL of serum was injected into HPLC. For the hydrolyzed samples, 120 gL of urine hydrolysate or 10 gL of serum hydrolysate (prepared as described above) was injected into the HPLC. Under these experimental conditions, the minimum amount of pentosidine detectable (signal-to-noise ratio = 4) was -0.33 pmol/injection. Figure 2A shows a typical chromatogram of a urine sample eluted from column 1 and monitored for ultraviolet absorbance with detector 1; at the zone marked in the chromatogram, the effluent flow is switched into column 2. The other panels in Fig.  2 show typical chromatograms of a pentosidine calibrator (B), a urine sample without hydrolysis (C), and a hydrolyzed serum sample (D) from an HD patient, after passage through column 2 as monitored with a fluorescence detector (detector 2). We generated a calibration curve by assaying seven urinary calibrations, prepared by adding 40 pmol to 4 nmol of pentosidine to 0.5 mL of urine from a healthy subject and injecting 70 gL of this onto the HPLC. Linear regression analysis showed significant linearity of the curve (r = 0.998, slope = 6.149, 2000 intercept = -0.292, SE = 0.17, P = 0.0001) (Fig. 3) We detected pentosidine in both hydrolyzed and unhydrolyzed urine samples from control subjects and HD patients but not in unhydrolyzed serum from control subjects. Pentosidine was detected in unhydrolyzed serum from HD patients, even though the concentration was much lower than in hydrolyzed C serum. Pentosidine exists in body fluids both free and peptidebound. In unhydrolyzed samples, free pentosidine is measured, whereas in hydrolyzed samples, the total for free and peptidebound pentosidine is measured. Table 1 shows the percentages of total pentosidine present as free pentosidine in urine and serum from HD patients and control subjects. In urine, the pentosidine and the duration of CRF in HD patients (r = 0.680, 95.7 ± 7.9 P = 0.0106) (Fig. 6A) but not between urinary pentosidine and 0' the duration of CRF in non-HD CRF patients (r = 0.173, P = 0.5221) (Fig. 6B) . The concentration of serum pentosidine was significantly correlated with the duration of CRF (r = 0.693, P = 0.0087) and HD (r = 0.7 18, P = 0.0057) (Fig. 6, C and D) . lFree (concentrationin sample without hydrolysis)/total (concentrationin hydrolyzed sample)) X 100.
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Pentosidine was not detected without hydrolysisin serum from control subjects.
percentage of free pentosidine was 95.3% in HD patients and 95.7% in control subjects; in serum, however, the percentage of free pentosidine was only 4.3% in HD patients and undetectable in the control subjects.
The mean ± SD concentrations of pentosidine in urine from control subjects and from DM, CRF, and OP patients (Fig. 4) were 5.2 ± 2.3, 8.7 ± 2.3, 36.1 ± 39.0, and 7.9 ± 5.3 gmol/mol creatinine, respectively. These means differed significantly between groups (P = 0.0001). In CRF, the mean concentration of urinary pentosidine in HD patients was significantly higher than Concentrations of urinary pentosidine in the control subjects (NC) and in the patients with DM, the patients with CRF undergoing HD or not (non-HD), and the OP patients. Bars Indicate means, which were significantly different (P = 0.0001) among groups.
Discussion
Pentosidine has been measured by HPLC in dura mater [1] , lens [2] , skin [3] , cartilage [12] , and glomerular basement membrane [13] under various conditions. However, the reports on measurements of pentosidine in body fluids have been few. Odetti et al. developed a combined reversed-phase ion-exchange HPLC method to measure pentosidine in serum hydrolysate [4] . In their method, reversed-phase HPLC fractions containing a pentosidine peak were collected and then rechromatographed on another cation-exchange HPLC. We previously reported the method in which SP-Sephadex C2 5 is the pretreatment before reversed-phase HPLC to measure pentosidine in hydrolysates of serum and urine [5, 6, 10] .By requiring two steps for detecting pentosidine in body fluids, these HPLC procedures are relatively tedious. The column-switching method described here does not require pre-or postchromatographic steps. Pentosidine in body fluids is measured by a single injection into a gelfiltration precolumn, which is then switched into a reversedphase column. The mean serum pentosidine concentrations measured in 13 end-stage renal failure patients by this method 
CRF duration (months)
and by our previous method [5] were 1182 ± 550 and 1238.7 ± 621 nmollL, respectively, significantly correlated (r = 0.9 14, P 0.000 1). Therefore, the pentosidine concentrations measured with this direct method are compatible with those of the previous method, but are obtained more conveniently.
A recent immunohistochemical study, using antibodies against pentosidine, demonstrated pentosidine in brain tissue [14] . Another study, involving an immunoassay (ELISA), measured pentosidine in serum and tissue hydrolysates [15] ; we have previously reported measuring pentosidine in urine [6, 10] .
Although most pentosidine reportedly exists in protein-bound form in blood [5] ,the free form predominates in urine [6] . In the present study, in which we measured pentosidine in urine and serum without and with hydrolysis by using column switching, we found, in accordance with the previous studies, that pentosidine circulates as the protein-bound form in blood and may be catabolized to its free form and excreted into urine. Thus, acid hydrolysis or digestion of the urine samples is not necessary to measure urinary excretion of pentosidine.
The concentrations of urinary pentosidine we measured in the patients with DM correspond to those determined in our previous study [6] . The mean urinary pentosidine concentration in OP patients was slightly higher than in control subjects; however, OP patients were older than control subjects (mean ages, 81.5 vs 55.3 years) and pentosidine is reported to accumulate in tissues during aging [3, 13] , which means that urinary pentosidine concentrations should increase with age [10] .
non-HD Pentosidine concentrations in CRF were higher than those in DM and OP. We previously suggested that pentosidine was produced in the body and excreted into urine to prevent its accumulation in tissues [6] . The fact that pentosidine is very high in collagen [I]and erythrocytes [4] from uremic patients suggests that pentosidine precursor sugars are retained by the diseased kidney and that the accumulation of pentosidine precursors may cause the increased synthesis of pentosidine in serum from uremic patients. Accordingly, the increased synthesis of pentosidine may lead to increased urinary excretion of pentosidine in CRF. However, the increased synthesis of pentosidine alone is not enough to explain the extreme increase of pentosidine in uremic serum. Because serum pentosidine concentrations did not change after HD in end-stage renal failure, HD could not eliminate pentosidine from serum [16] .Pentosidine may be mostly eliminated or catabolized through the kidney, and a diseased kidney may mean that pentosidine is retained in the blood circulation.
In non-HD patients with CRF, high concentrations of urinary pentosidine may be mainly caused by increased synthesis of pentosidine.
The absence of correlation of urinary pentosidine with CRF duration in non-HD patients suggests that most of pentosidine can be excreted into urine; therefore, serum concentrations are below the excretion threshold in such patients. On the other hand, urinary concentrations of pentosidine in HD patients did correlate with the duration of CRF and HD, the urinary pentosidine concentrations in HD patients being et a!.: Pentosidine quantified by HPLC with column switching (surprisingly) threefold higher than in non-HD patients. Pentosidine could not be fully excreted by the diseased kidney in HD patients. The significant correlation between urinary pentosidine and serum pentosidine thus indicates that the accumulated pentosidine in serum is directly responsible for the increased excretion.
